WuXi XDC Cayman Inc. Share Price

Equities

2268

KYG9808A1058

Pharmaceuticals

End-of-day quote Hong Kong S.E. 03:30:00 31/05/2024 am IST 5-day change 1st Jan Change
15.32 USD +2.68% Intraday chart for WuXi XDC Cayman Inc. +1.32% -52.12%

Financials

Sales 2024 * 3.16B 436M 36.4B Sales 2025 * 4.61B 637M 53.14B Capitalization 16.99B 2.35B 196B
Net income 2024 * 576M 79.54M 6.63B Net income 2025 * 918M 127M 10.57B EV / Sales 2024 * 4.31 x
Net cash position 2024 * 3.37B 465M 38.79B Net cash position 2025 * 3.2B 442M 36.87B EV / Sales 2025 * 2.99 x
P/E ratio 2024 *
29.1 x
P/E ratio 2025 *
18.4 x
Employees 1,178
Yield 2024 *
-
Yield 2025 *
-
Free-Float 15.51%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.68%
1 week+1.32%
1 month-30.05%
3 months-15.82%
6 months-46.43%
Current year-52.12%
More quotes
1 week
14.10
Extreme 14.1
15.92
1 month
14.10
Extreme 14.1
23.20
Current year
12.08
Extreme 12.08
33.10
1 year
12.08
Extreme 12.08
34.00
3 years
12.08
Extreme 12.08
34.00
5 years
12.08
Extreme 12.08
34.00
10 years
12.08
Extreme 12.08
34.00
More quotes
Date Price Change Volume
31/24/31 15.32 +2.68% 3,860,889
30/24/30 14.92 -1.71% 1,839,167
29/24/29 15.18 +0.93% 4,822,142
28/24/28 15.04 +3.30% 3,491,500
27/24/27 14.56 -3.70% 4,790,500

End-of-day quote Hong Kong S.E., May 31, 2024

More quotes
WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The Company conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The Company conducts its business in domestic and foreign markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
14.19 CNY
Average target price
28.8 CNY
Spread / Average Target
+102.97%
Consensus

Quarterly revenue - Rate of surprise